SCHEMBL24347367

SCHEMBL24347367

CC(C)NCCNc1ccn(C)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
HTT P42858 1/20 0.45
KAT2B Q92831 1/20 0.44
NPC1 O15118 6/20 0.36
RAB9A P51151 5/20 0.36
RXRA P19793 2/20 0.36
GRIN1 Q05586 2/20 0.36
GRIN2B Q13224 2/20 0.36
NOTUM Q6P988 1/20 0.33
MAPK1 P28482 1/20 0.33
EPHX2 P34913 1/20 0.33
CTSK P43235 1/20 0.32
CHRM2 P08172 1/20 0.32
CHRM4 P08173 1/20 0.32
CHRM1 P11229 1/20 0.32
CHRM3 P20309 1/20 0.32
SIGMAR1 Q99720 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22253416 0.81 ALDH1A1 (0.46) SMN1; SMN2KDM4EALDH1A1LMNAHTT
SCHEMBL22242106 0.80 SMN1; SMN2 (0.49) SMN1; SMN2KDM4EALDH1A1LMNAHTT
SCHEMBL22255199 0.78 KDM4E (0.50) SMN1; SMN2KDM4EALDH1A1LMNAHTT
SCHEMBL4419213 0.77 ALDH1A1 (0.53) SMN1; SMN2KDM4EALDH1A1LMNAHTT
SCHEMBL23666643 0.75 ALDH1A1 (0.47) SMN1; SMN2KDM4EALDH1A1LMNAHTT
SCHEMBL15885943 0.74 ALDH1A1 (0.46) SMN1; SMN2KDM4EALDH1A1LMNAHTT
SCHEMBL17115796 0.74
SCHEMBL8142402 0.74 SMN1; SMN2 (0.44) SMN1; SMN2KDM4EALDH1A1LMNAHTT
SCHEMBL21137768 0.72 KDM4E (0.45) SMN1; SMN2KDM4EALDH1A1LMNAHTT
SCHEMBL21061054 0.72 ALDH1A1 (0.45) SMN1; SMN2KDM4EALDH1A1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220119367-A1 HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS INTEGRAL BIOSCIENCES PVT. LTD. (IN) 2022-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119367-A1 HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS ADORA2A, ADORA3, ADORA1 SMN1; SMN2 4476/4885KDM4E 4200/4885ALDH1A1 2100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.